Isembyld (apitegromab-mstn)
Scholar Rock (SRRK)
ApprovedSep 11, 2026
Marketer take
An add-on for SMA patients already on SMN2-targeted therapy, so it sells alongside existing SMA brands rather than against them; neuromuscular centers and caregiver communities are the key audiences.
- Sponsor company
- Scholar Rock (SRRK)
- Indication
- To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Therapeutic area
- Neurology, Rare disease
- Event
- FDA approval
- Date
- Sep 11, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?